Detection of microRNA expressions in tissues and exfoliative cells reveals the potential role of miR-203 in oral lichen planus

doi:10.5246/jcps.2014.05.038

Journal of Chinese Pharmaceutical Sciences ›› 2014, Vol. 23 ›› Issue (5): 279-286.DOI: 10.5246/jcps.2014.05.038

• Original articles • Previous Articles Next Articles

Detection of microRNA expressions in tissues and exfoliative cells reveals the potential role of miR-203 in oral lichen planus

Zhendong Feng¹, Wen Shi^1,2, Zhigang Cai², Hong Hua², Demin Zhou^1*

1. State Key Laboratory of Natural and Biomimetic Drugs; Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
2. School and Hospital of Stomatology, Peking University, Beijing 100191, China

Received:2013-12-02 Revised:2014-02-15 Online:2014-05-23 Published:2014-02-20
Contact: Tel./Fax: 86-10-82805519; E-mail: deminzhou@bjmu.edu.cn
About author:*Corresponding author. Tel./Fax: 86-10-82805519; E-mail: deminzhou@bjmu.edu.cn
Supported by:
National Natural Science Foundation of China (Grant No. 91029711).

Abstract

Abstract:

Oral lichen planus (OLP) is a chronic inflammatory disorder and premalignantlesion, of which the mechanisms are still obscure. In the present study, the expression levels of miR-96/182/183 cluster, miR-203, miR-375, and miR-769-5p in both tissues and exfoliative cells of OLP patients as well as healthy volunteers were detected, differentially expressed miRNAs were identified and their correlation with OLP was evaluated by a biplot method. Experimental results show that miR-203 is significantly up-regulated in patient lesion tissues in comparison to volunteer mucosa tissues. Moreover, the contradictory insignificant expression changes of miR-203 as well as miR-96/182/183 cluster in comparisons of exfoliative cell samplessuggest that different cell compositions in OLP lesion have distinct miRNA regulation, which accords with the histological heterogeneity of OLP. Finally, biplot analyses indicate the expression of miR-203 and miR-96/182/183 cluster are positively correlated in patient lesions. These results provide miR-203 as a molecular indicator of heterogeneity of OLP, and also a potential diagnostic biomarker or therapeutic target that deserves further studies.

Key words: Oral lichen planus, microRNA, RT-qPCR, Biplot method, miR-203

CLC Number:

R739
R988.2

Supporting:

Zhendong Feng, Wen Shi, Zhigang Cai, Hong Hua, Demin Zhou. Detection of microRNA expressions in tissues and exfoliative cells reveals the potential role of miR-203 in oral lichen planus[J]. Journal of Chinese Pharmaceutical Sciences, 2014, 23(5): 279-286.

References

[1] Duffey, D.C.; Eversole, L.R.; Abemayor, E. Laryngoscope. 1996, 106, 357−362.

[2] Eisen, D.; Carrozzo, M.; Bagan Sebastian, J.V.; Thongprasom, K. Oral Dis. 2005, 11, 338−349.

[3] Mignogna, M.D.; Fedele, S.; Lo Russo, L.; Mignogna, C.; de Rosa, G.; Porter, S.R. Eur. J. Surg. Oncol. 2007, 33, 383−389.

[4] Mignogna, M.D.; Fedele, S.; Lo Russo, L. Oral Oncol. 2006, 42, 819−824.

[5] Holmstrup, P.; Thorn, J.J.; Rindum, J.; Pindborg, J.J. J. Oral Pathol. 1988, 17, 219−225.

[6] Kim, V.N. Nat. Rev. Mol. Cell Biol. 2005, 6, 376−385.

[7] Garzon, R.; Calin, G.A.; Croce, C.M. Annu Rev. Med. 2009, 60, 167−179.

[8] Gomes, C.C.; de Sousa, S.F.; Gomez, R.S. Curr. Pharm. Des. 2013, 19, 1285−1291.

[9] Perez-Sayans, M.; Pilar, G.D.; Barros-Angueira, F.; Suarez-Penaranda, J.M.; Fernandez, A.C.; Gandara-Rey, J.M.; Garcia-Garcia, A. J. Oral Pathol. Med. 2012, 41, 433−443.

[10] Arao, T.C.; Guimaraes, A.L.; de Paula, A.M.; Gomes, C.C.; Gomez, R.S. Arch. Dermatol. Res. 2012, 304, 371−375.

[11] Henry, J.C.; Azevedo-Pouly, A.C.; Schmittgen, T.D. Pharm. Res. 2011, 28, 3030−3042.

[12] Bader, A.G.; Brown, D.; Winkler, M. Cancer Res. 2010, 70, 7027−7030.

[13] Rio, D.C.; Ares, M.Jr.; Hannon, G.J.; Nilsen, T.W. Cold Spring Harb Protoc. 2010, 2010, pdb prot 5439.

[14] Chen, C.Z.; Li, L.; Lodish, H.F.; Bartel, D.P. Science. 2004, 303, 83−86.

[15] Pasquinelli, A.E.; Ruvkun, G. Annu. Rev. Cell Dev. Biol. 2002, 18, 495−513.

[16] Zhu, D.X.; Miao, K.R.; Zhu, Y.D.; Zhu, H.Y.; Fan, L.; Liu, P.; Xu, W.; Li, J.Y. J. Exp. Hematol. 2010, 18, 757−761.

[17] Neely, J.G.; Hartman, J.M.; Forsen, J.W.Jr.; Wallace, M.S. Laryngoscope. 2003, 113, 1719−1725.

[18] Shuke, N. Kaku Igaku. 1991, 28, 391−400.

[19] Sanchez-Mora, C.; Ramos-Quiroga, J.A.; Garcia-Martinez, I.; Fernandez-Castillo, N.; Bosch, R.; Richarte, V.; Palomar, G.; Nogueira, M.; Corrales, M.; Daigre, C.; Martinez-Luna, N.; Grau-Lopez, L.; Toma, C.; Cormand, B.; Roncero, C.; Casas, M.; Ribases, M. Eur. Neuropsychopharmacol. 2013, 23, 1463−1473.

[20] Tang, H.; Bian, Y.; Tu, C.; Wang, Z.; Yu, Z.; Liu, Q.; Xu, G.; Wu, M.; Li, G. Curr. Cancer Drug Targets. 2013, 13, 221−231.

[21] Mihelich, B.L.; Khramtsova, E.A.; Arva, N.; Vaishnav, A.; Johnson, D.N.; Giangreco, A.A.; Martens-Uzunova, E.; Bagasra, O.; Kajdacsy-Balla, A.; Nonn, L. J. Biol. Chem. 2011, 286, 44503−44511.

[22] Qu, Y.; Li, W.C.; Hellem, M.R.; Rostad, K.; Popa, M.; McCormack, E.; Oyan, A.M.; Kalland, K.H.; Ke, X.S. Int. J. Cancer. 2013, 133, 544−555.

[23] Bian, Z.; Li, L.; Cui, J.; Zhang, H.; Liu, Y.; Zhang, C.Y.; Zen, K. J. Pathol. 2011, 225, 544−553.

[24] Wei, J.; Huang, X.; Zhang, Z.; Jia, W.; Zhao, Z.; Zhang, Y.; Liu, X.; Xu, G. Mol. Immunol. 2013, 55, 303−309.

[25] Bezman, N.A.; Chakraborty, T.; Bender, T.; Lanier, L.L. J. Exp. Med. 2011, 208, 2717−2731.

[26] Liu, Y.; Zhao, L.; Li, D.; Yin, Y.; Zhang, C.Y.; Li, J.; Zhang, Y. Protein Cell. 2013, 4, 932− 941.

[27] Wang, Y.; Huang, C.; Reddy Chintagari, N.; Bhaskaran, M.; Weng, T.; Guo, Y.; Xiao, X.; Liu, L. Nucleic Acids Res. 2013, 41, 3833− 3844.

[28] Komatsu, S.; Ichikawa, D.; Takeshita, H.; Konishi, H.; Nagata, H.; Hirajima, S.; Kawaguchi, T.; Arita, T.; Shiozaki, A.; Fujiwara, H.; Okamoto, K.; Otsuji, E. Expert. Opin. Biol. Ther. 2012, 12 Suppl 1, S53−59.

[29] Xie, H.; Lee, L.; Caramuta, S.; Hoog, A.; Browaldh, N.; Bjornhagen, V.; Larsson, C.; Lui, W.O. J. Invest. Dermatol. 2014, 134, 507−517.

[30] Xiao, B.; Wang, Y.; Li, W.; Baker, M.; Guo, J.; Corbet, K.; Tsalik, E.L.; Li, Q.J.; Palmer, S.M.; Woods, C.W.; Li, Z.; Chao, N.J.; He, Y.W. Blood. 2013, 122, 3365−3375.

[31] Qu, Y.; Li, W.C.; Hellem, M.R.; Rostad, K.; Popa, M.; McCormack, E.; Oyan, A.M.; Kalland, K.H.; Ke, X.S. Int. J. Cancer. 2013, 133, 544−555.

Detection of microRNA expressions in tissues and exfoliative cells reveals the potential role of miR-203 in oral lichen planus

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 2

Recommended Articles

Metrics

Comments

[1]	Weiwei Jiang, Haiyan Quan, Lu He, Xing Jiang. The diagnostic and prognostic value of CCTs in human hepatocellular carcinoma: a study based on integrated bioinformatics [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(10): 782-797.
[2]	State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center. The group of Professor Xinjing Tang has made progress in the study of cyclic antisense oligonucleotides as microRNA inhibitors [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(10): 855-856.